ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at ST2825 (5 μM) and 80% inhibition at ST2825 (10 μM ) [1].

ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. ST2825 exerts a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β [1].